No announcement yet.

Pandemic Influenza: A Potential Role for Statins (full article)

  • Filter
  • Time
  • Show
Clear All
new posts

  • Pandemic Influenza: A Potential Role for Statins (full article)

    Pandemic Influenza: A Potential Role for Statins
    in Treatment and Prophylaxis

    Clinical Infectious Diseases 2006; 43:000–000
    Received 19 December 2005; accepted 14 March 2006;
    electronically published 12 June 2006.

    David S. Fedson

    The next influenza pandemic may be imminent. Because antiviral agents and vaccines will be unavailable to people in most countries, we need to determine whether other agents could offer clinical benefits. Influenza is associated with an increase in acute cardiovascular diseases, and influenza viruses induce proinflammatory cytokines. Statins are cardioprotective and have anti-inflammatory and immunomodulatory effects, and they thus might benefit patients with influenza. This hypothesis should be evaluated by using administrative databases to search for reduced rates of hospitalization and death due to influenzarelated conditions among people taking statins. These studies should be followed by laboratory studies of statins in animal and cell-based models of influenza virus infection and, later, by clinical trials. Positive results from such studies would provide physicians in all countries with something to offer patients for treatment and prophylaxis of pandemic influenza. Generic statins will be widely distributed and inexpensive. They might be the only agents that could alter the course of a global pandemic.

    Influenza experts and health officials throughout the world are extremely concerned about global spread of avian H5N1 influenza and the possibility that it could lead to the next pandemic [1, 2]. If a pandemic like the 1918 pandemic were to occur today, it would kill 175–350 million people worldwide [3]. If the case-fatality rate associated with the next pandemic is like that associated with the human cases of H5N1 influenza recently seen in Southeast Asia, it would kill even more people [4]. Speculation like this may seem farfetched, but avian influenza viruses have caused devastating outbreaks of disease in mammalian species other than man. In the early 1980s, for example, an avian H7N7 influenza epidemic killed ∼20% of the harbor seals living along the North Atlantic coast [5].

    We cannot predict whether the next influenza pandemic will be mild, like the 1968 pandemic; moderate, like the 1957 pandemic; severe, like the 1918 pandemic; or overwhelmingly catastrophic [6]. We can be certain, however, that it will occur sooner or later. When this happens, we will have very limited supplies of antiviral agents [4], and antiviral resistance might compromise their usefulness against H5N1 influenza viruses [7]. Moreover, we will have to wait many months before limited supplies of vaccines become available [8]. If an H5N1 influenza pandemic is imminent, prospects for obtaining adequate supplies of antigen-sparing pandemic vaccines are becoming increasingly remote [9]. Practically speaking, most people in the world will have little or no access to antiviral agents or vaccines.

    For this reason, we need to determine whether currently available agents could be used for treatment and prophylaxis of pandemic influenza.


    Influenza virus infections are associated with an increase in acute cardiovascular and cerebrovascular (hereafter called “cardiovascular”) diseases, and the winter-season mortality associated with these events is greater than that ascribed to influenzarelated pneumonia and other respiratory conditions [10, 11]. When influenza is prevented by vaccination, hospitalizations and deaths due to influenza-related cardiovascular diseases are reduced [10, 12].

    Influenza viruses are potent inducers of many biological response mediators that make up the innate immune system [13]. In both experimental [14, 15] and naturally occurring [16] human influenza virus infections, increased serum levels of several proinflammatory cytokines (e.g., TNF-a and IL-6) have been positively correlated with the symptoms of clinical illness. In an experimental model of human influenza A virus infection, H3N2 viruses were shown to be more potent inducers of TNF-a and IL-6 than were H1N1 viruses [17]. The avian H5N1 influenza viruses that have caused fatal disease in humans are exceptionally potent inducers of proinflammatory cytokines [18–21]. Cytokine dysregulation is now regarded as a major contributor to the severe pathophysiological changes seen inhumandisease caused by the avian H5N1 [2, 18–21] and 1918 pandemic influenza viruses [22, 23].


    Inflammation plays an important role in the pathogenesis of all stages of cardiovascular diseases [24, 25]. Proinflammatory cytokines reduce the beneficial effects of endothelial nitric oxide synthase and thrombomodulin that help maintain normal blood flow [25]. They also increase expression of surface adhesion molecules (e.g., vascular cell adhesion molecule–1) that recruit leukocytes to vessel walls. Leukocytes, in turn, elaborate proinflammatory factors (e.g., C-reactive protein, IL-6, and soluble CD40 ligand) that set the stage for acute intravascular thrombosis. During these events, increased levels of several cytokines can be demonstrated in patient serum samples.

    The clinical benefits of statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) for patients with cardiovascular diseases are firmly established. A recent meta-analysis of 90,056 individuals enrolled in 14 randomized controlled trials showed that, over a 5-year period, statins were associated with a 21% reduction in major cardiovascular events, including a 19% reduction in mortality associated with coronary events and a 17% reduction in fatal or nonfatal stroke [26].

    This level of protection was observed not only because statins reduce levels of lowdensity lipoprotein cholesterol but also because they have a wide variety of antiinflammatory and immunomodulatory effects [25].

    Statins improve endothelial cell function by decreasing cellular adhesion (decreased vascular cell adhesion molecule–1) and thrombosis (decreased tissue factor) and increasing vasoreactivity (increased endothelial nitric oxide synthase). They affect immune and inflammatory cells by reducing monocyte and macrophage recruitment and the expression of numerous cytokines and chemokines (e.g., IL-1, IL-6, TNF-a, IFN-g, RANTES [regulated on activation, normally T cell expressed and secreted], and soluble CD40 ligand). They also inhibit smooth muscle cell proliferation and platelet hyperreactivity.

    At the molecular level, statins interact with the synthesis of isoprenylated proteins that serve as lipid attachments for small guanosine triphosphate–binding Ras and Ras-like (e.g., Rho and Rac) proteins. Through their actions, they improve vascular function (increased endothelial nitric oxide synthase) and decrease leukocyte adhesion and fibrinolytic activity. In addition, they affect nuclear events that regulate gene expression and cell function. Proinflammatory stimuli cause Rho and Rho-like proteins to induce nuclear factor–kB (NF-kB), which then translocates to the cell nucleus and induces the expression of target genes, including those for several cytokines. Statins limit these activities.

    Statins also reduce the expression of regulatory proteins that compose the activator protein 1 complex and induce the expression of other nuclear factors (e.g.,Kruppel-like factor–2) that exert broad effects on endothelial cell function (increased endothelial nitric oxide synthase and decreased vascular cell adhesion molecule–1). These activities counterbalance those of NF-kB. Statin-mediated induction of endothelial nitric oxide synthase and thrombomodulin depends on Kruppel-like factor–2 [25].

    A large body of evidence now suggests that the long-term cardiovascular benefits of statins are associated with their antiinflammatory and immunomodulatory effects [24, 25]. However, statins can also induce remarkable short-term improvements in cardiovascular function. For example, the use of short-term, low-dose simvastatin treatment for patients with nonischemic dilated cardiomyopathy resulted in clinical improvement that was associated with substantial reductions in serum levels of several inflammatory mediators, including TNF-a and IL-6 [27]. The anti-inflammatory effects of pravastatin on coronary endothelial dysfunction [28] and of simvastatin on C-reactive protein levels [29] have been demonstrated in patients even after administration of a single dose. Moreover, an epidemiological study of 1300,000 patients with acute myocardial infarction has shown that those who continued receiving or were newly receiving statins within 24 h of hospitalization had a 13-fold reduction in mortality, compared with patients who were not treated [30]. These short-term effects of statins might have important implications for the management of other acute life-threatening events associated with inflammation.


    In addition to their effects on cardiovascular diseases, there is growing evidence that statins could be beneficial in the treatment of patients with life-threatening infections, some of which are associated with cytokine dysregulation. For example, in infants with bacterial sepsis, serum levels of several proinflammatory cytokines were higher than they were in infants with culture- negative sepsis syndrome, and levels were highest in those infants who died [31]. In adults with sepsis, depressed myocardial contractility was associated with increased levels of several proinflammatory cytokines, and serum samples obtained from these patients activated transcription factors and induced human fetal cardiac myocyte apoptosis [32]. Experimental studies suggest that statins favorably alter the course of bacterial sepsis. In a murine model of acute bacterial sepsis (cecal ligation and puncture without subsequent administration of antibiotics), prophylaxis [33] and treatment [34] with simvastatin dramatically preserved cardiac and hemodynamicfunction and significantly prolonged survival. In addition, 3 clinical reports have suggested that statins were of benefit in patients with acute bacterial sepsis (table 1) [35–37].

    The first study included 388 patients who were hospitalized with gram-negative or Staphylococcus aureus bacteremia [35]. The second study included 361 patients who were hospitalized with presumed or documented acute bacterial infections [36]. The third study included 438 patients who were hospitalized with bacterial sepsis [37]. Remarkably, if statin treatment was continued in the hospital, the rate of death attributable to bacteremia was reduced by 87% in the first study [35] and 92% in the third study [37]. In addition, a population-based, nested, case-control study of 69,168 elderly patients discharged after hospitalization for acute cardiovascular events showed that the risks of subsequent hospitalization for sepsis and for fatal sepsis were lower for statin-treated patients than they were for untreated control patients (table 1) [38]. Another population-based study did not find a beneficial effect of statins on 30-day sepsisassociated mortality, but the number of statin-treated patients was small and the 95% CIs around the point estimates were very broad (table 1) [39]. Many physicians have begun to ask whether treatment of sepsis should include statins [41].

    The mechanism(s) by which statins exert beneficial effects in patients with bacteremia and sepsis are not well understood. Animal models of acute lipopolysaccharide-induced sepsis (similar to endotoxemia) and bacterial sepsis have shown that a variety of inflammatory mediators are implicated in fatal disease [42].

    Nonetheless, many treatment interventions targeting specific abnormalities suggested by animal studies (e.g., TNF-a) have not been efficacious when tested in clinical trials in humans. To date, only low-dose corticosteroids and activated protein C have been shown to benefit patients with severe sepsis [42]. However, several newer therapeutic targets are now being considered, including Toll-like receptors, high-mobility group box 1 protein, macrophage migration inhibitory factor, complement C5a and C5a receptors, and inhibitors of apoptosis [43, 44]. Statins have effects on several of these targets.


    Cytokines also act as inflammatory mediators in acute lung injury, as shown in both experimental and clinical studies [45–49]. In a recent report, simvastatin dramatically reduced the response of human pulmonary artery endothelial cells to thrombin-induced endothelial barrier and cytoskeletal dysfunction, an effect that required gene expression and protein synthesis [50]. Simvastatin also induced pronounced endothelial barrier protection in a murine model of acute lung injury caused by intratracheal administration of lipopolysaccharide [51]. In this model, simvastatin significantly altered lipopolysaccharide- mediated expression of several genes associated with inflammatory change (e.g., IL-6 and Toll-like receptor 4). In another model of acute lung injury in rats after intestinal ischemia and reperfusion, pretreatment with simvastatin was associated with reduced leukocyte infiltration into lung tissue, decreased production of free oxygen radicals, and reduced severity of acute lung injury [52].

    Clinical studies of healthy elderly people have shown that those with elevated levels of proinflammatory cytokines (TNF-a and IL-6) have an increased risk of being admitted to the hospital later for community-acquired pneumonia [53]. Moreover, among hospitalized patients with pneumonia, those with elevated proinflammatory cytokines have an increased risk of developing septic shock [54]. A recent retrospective study of 787 patients with community-acquired pneumonia showed that 30-day mortality was reduced by 64% among those who were previously taking statins (table 1) [40].

    The anti-inflammatory and immunomodulatory effects of statins on the host response to acute lung injury are becoming increasingly evident. Given the clinical associations between influenza and cardiovascular diseases and the cytokine-mediated inflammatory changes associated with both, is it possible that the benefits of statins, so evident for cardiovascular diseases, bacteremia, sepsis, and pneumonia, might also extend to patients with influenza? To date, no reports have been published describing the direct effects of statins on the molecular and clinical pathophysiological profiles of experimental or clinical influenza virus infections. Nonetheless, the findings outlined above suggest the possibility that treatment and prophylaxis with statins might alter the clinical course and outcome of interpandemic and pandemic influenza [55].


    This hypothesis could be evaluated in several ways. Initially, the most direct and, probably, most efficient approach would be to look for epidemiological signals of the protection provided by statins against influenza-related events in populations during interpandemic years. For example, cardiologists could evaluate the occurrence of these events in treated and control subjects who have participated in large, prospective, randomized controlled trials of statins. Unfortunately, these studies might not be conclusive, because patients enrolled in the trials have been younger, rather than older, adults and have experienced relatively few hospitalizations or deaths due to respiratory conditions [26].

    As an alternative, investigators could follow the epidemiological model of the statins/sepsis study mentioned above [38] and undertake retrospective cohort and case-control studies of the effects of statins in people whose health care and medical treatments have been documented in large administrative databases. The primary goal of these studies would be to see whether there were differences between untreated and statin-treated subjects, with regard to rates of influenza-related hospitalization and death, especially those due to pneumonia and influenza and other respiratory conditions. The outcomes would need to be evaluated during and outside of influenza seasons, and careful adjustment for confounding variables, including influenza vaccination, would be essential.

    It is hoped that the epidemiological studies would show a benefit of statins on influenza-related outcomes. However, they might show that statin treatment could be harmful. For example, statins could impair host defenses and lead to an increase in secondary bacterial pneumonias [56], or they could down-regulate cytokines and lead to uncontrolled virus replication and increased mortality [23]. Alternatively, discontinuation of statin treatment could be quickly followed by clinical deterioration [37], as has been shown by the rapid loss of statin-induced anti-inflammatory and immunomodulatory effects in experimental models of endothelial dysfunction [57] and stroke [58]. Whatever the epidemiological findings, they could be used to generate hypotheses for a wide range of laboratory and clinical studies.

    Two epidemiological studies have been undertaken to test the statin/influenza hypothesis. One study has been conducted by investigators in The Netherlands, who have used a large general practice administrative database. The other has been conducted by Swiss investigators, who have used the United Kingdom’s General Practice Research Database. The Swiss investigators recently completed a population-based, nested, case-control study of pneumonia (R. G. Schlienger and C. M. Meier, personal communication). They studied cases that occurred throughout the year, not just those that occurred during influenza seasons. They found that people who were currently taking statins (defined as statins having been prescribed within 30 days of the date of onset of pneumonia) had a statistically significant reduced risk of 30-day pneumonia-associatedmortality and a lower but not quite statistically significant risk of being hospitalized with pneumonia and surviving. Protection was not shown for those who had taken statins in the past (defined as statins having been prescribed 30 days before the date of onset of pneumonia) but were currently not taking them, nor was it shown for those who had taken a control medication at any time. Preliminary findings from the Dutch epidemiological study have also suggested that statin treatment was associated with reductions in influenza-related pneumonia, acute myocardial infarction, and stroke [59].


    The results obtained from the 2 epidemiological studies mentioned above can only suggest that patients who are treated with statins for the prevention of cardiovascular diseases are also protected against respiratory diseases often associated with influenza. Given the limitations of the data available to investigators, the studies could not determine whether statin treatment was continued after hospital admission, although, in many instances, it probably was [37].

    The “epidemiological signals of protection” obtained in the Swiss and Dutch studies need to be confirmed in other population- based studies. Nonetheless, together with the clinical studies summarized in table 1, they provide enough evidence to justify undertaking laboratory studies of statin treatment and prophylaxis in animal models of influenza caused by interpandemic (H3N2) [60], avian H5N1 [61], and 1918 pandemic–like [23, 2] viruses.

    The challenge viruses should include related reassortants with different degrees of virulence. Wherever possible, the studies should evaluate the effects of statins on the cellular and molecular manifestations of disease and should compare the results with their corresponding gene expression profiles [63, 64]. Special attention should be given to the effect of statins on secondary bacterial pneumonia [65].

    The results of these studies will need to be cautiously interpreted, as is indicated by experience gained in interpreting the conflicting results of animal model and human studies of therapeutic interventions for sepsis [42].

    If animal studies of influenza indicate that statins are protective, investigators should explore the molecular effects of statins in influenza virus–infected cells. Cholesterol synthesis is essential for the normal functioning of cell membranes, especially lipid rafts [66]. Cholesterol is also essential for influenza virus assembly, budding from raft-derived microdomains, and virus infectivity for other cells [67–69]. Experimental studies in mice have shown that Toll-like receptor 7, which is located in the endosomal compartment of the cell, recognizes single-stranded influenza virus RNA [70]. Once recognized, Toll-like receptor 7 recruits several adaptor molecules (e.g., myeloid differentiation protein 88 [MyD88]) that, through a series of signalling steps, lead to the translocation of NF-kB to the nucleus, an essential event in establishing influenza virus infection [71]. The “MyD88-dependent pathway” controls gene expression for several proinflammatory cytokines and chemokines (e.g., TNF-a, IL-6, and IL-1b), type 1 interferons, plasmacytoid dendritic cell maturation, and antiviral immunity [70].

    These and many other intracellular signalling cascades have been identified in cells infected with influenza virus [72]. One of the most important intracellular signalling pathways involves influenza virus–induced caspase activation and subsequent apoptosis. Caspase 3 activation is essential for influenza virus replication. Apoptosis is thought to be responsible for the induction of lymphocyte depletion (prominent in human H5N1 influenza virus infection [4]) and the down-regulation of proinflammatory cytokines. The overall host benefits of apoptosis, however, are still uncertain [72]. From what is already known, statins have the potential to affect many of these and other molecular pathways in influenza virus–infected cells [25].

    Clinical investigators also should begin to gather information on cytokine profiles and levels of other potential immunomodulatory molecules (e.g., high-mobility group box 1 protein [73], hyaluron degradation products [74], and angiopoeitin-2 [75]) in patients with seasonal and avian H5N1 influenza, giving attention to establishing correlates with disease severity and prognosis. Eventually, they might begin planning clinical trials of statin treatment and prophylaxis. Studies of statin safety, as well as statin efficacy, in children would be especially important. Physicians caring for patients with life-threatening avian H5N1 infections could even consider treating such patients with statins on a compassionate basis.

    Statins might not be the only medication useful in the treatment and prophylaxis of pandemic influenza. Epidemiologists, laboratory investigators, and clinicians should look for evidence that other existing agents, such as angiotensin-converting enzyme inhibitors [76], angiotensin II receptor blockers [77], aldosterone antagonists [78], or phosphodiesterase inhibitors [79], might be beneficial, either alone or in combination. Ideally, these agents should be generically produced, widely available in developing countries, and inexpensive. Research on statins and other agents might also have
    relevance for other serious virus diseases, such as severe acute respiratory syndrome [80–82] and HIV/AIDS [83].


    When the next pandemic arrives, physicians who live in countries without antiviral stockpiles or vaccine companies will have little or nothing to offer their patients.

    If epidemiological, laboratory, and clinical studies confirm the benefits of statins for the treatment of influenza, physicians everywhere will have something to offer their patients for the pandemic.

    Statins are already widely distributed throughout the world and are used to treat millions of people on a year-round basis. Moreover, the patents for several statins will expire in a year or two, and several are already being produced as generics in some developing countries. The cost advantage of statins, compared with existing antiviral agents, will be remarkable. Currently, in the United States, a 5-day course of the antiviral agent oseltamivir costs ∼$60–$90, whereas a 5-day course of generic simvastatin will cost as little as $1.75 [84]. In developing countries, the cost advantage of generic statins will be even greater.

    The scientific rationale for considering statins for treatment and prophylaxis of pandemic influenza is persuasive, but the public health rationale is overwhelmingly compelling. Given their low cost, safety, and worldwide availability, generic statins could become crucially important for confronting the next pandemic. They could greatly reduce the disparity that will otherwise separate developed and developing countries. They could become the only currently available agents to alter the course of what otherwise might become an unprecedented global health crisis. For public health reasons alone, the research agenda outlined in the present report is one that we cannot afford not to undertake, and we must do so with a great sense of urgency.

    Potential conflicts of interest. D.S.F. has received
    travel support and modest honoraria from
    Sanofi Pasteur International for lectures on pandemic
    influenza and influenza vaccination delivered
    at scientific meetings (!5 meetings per year).
    From December 2002 to December 2004, he
    worked as a part-time consultant to the Influenza
    Vaccine Supply International Task Force, which he
    had been instrumental in organizing. From 1995
    to November 2002, he worked as Director of Medical
    Affairs for Aventis Pasteur MSD, a European
    vaccine company. He currently has no consulting
    agreements or financial arrangements with any
    company or institution. He owns no stock in any
    vaccine or pharmaceutical company.


    1. Li KS, Guan Y, Wang J, et al. Genesis of a
    highly pathogenic and potentially pandemic
    H5N1 influenza virus in eastern Asia. Nature
    2004; 430:209–13.
    2. Lipatov AS, Govorkova EA, Webby RJ, et al.
    Influenza: emergence and control. J Virol
    2004; 78:8951–9.
    3. Johnson NPAS, Mueller J. Updating the accounts:
    global mortality of the 1918–1920
    “Spanish” influenza pandemic. Bull Hist Med
    2002; 76:105–15.
    4. Beigel JH, Farrar J, Han AM, et al. Avian influenza
    A (H5N1) infections in humans. N
    Engl J Med 2005; 353:1373–85.
    5. Geraci JR, St. Auban DJ, Barker IK, et al. Mass
    mortality of harbor seals: pneumonia associated
    with influenza A virus. Science 1982; 215:
    6. Nguyen-Van-Tam JS, Hampson AW. The epidemiology
    and clinical impact of pandemic
    influenza. Vaccine 2003; 21:1762–8.
    7. de Jong MD, Thanh TT, Khanh TH, et al.
    Oseltamivir resistance during treatment of influenza
    A (H5N1) influenza. N Engl J Med
    2005; 353:2667–72.
    8. Fedson DS. Preparing for pandemic vaccination:
    an international policy agenda for vaccine
    development. J Public Health Policy
    2005; 26:4–29.
    9. Fedson DS. Vaccine development for an imminent
    pandemic; why we should worry, what
    we must do. Human Vaccines 2006; 2:38–42.
    10. Madjid M, Naghavi M, Litovsky S, CasscellsSW.
    Influenza and cardiovascular disease: a new opportunity
    for prevention and the need for further
    studies. Circulation 2003; 108:2730–6.
    11. Reichert TA, Simonsen L, Sharma A, Pardo
    SA, Fedson DS, Miller MA. Influenza and the
    winter increase in mortality in the United
    States, 1959–1999. Am J Epidemiol 2004; 160:
    12. Nichol KL. The efficacy, effectiveness and costeffectiveness
    of inactivated influenza virus vaccines.
    Vaccine 2003; 21:1769–75.
    13. Julkunen I, Sareneva T, Pirhonen J, Ronni T,
    Melen K, Matikainen S. Molecular pathogenesis
    of influenza A virus infection and virusinduced
    regulation of cytokine gene expression.
    Cytokine Growth Factor Rev 2001; 12:
    14. Hayden FG, Fritz RS, Lobo M, Alvord G,
    Strober W, Straus SE. Local and systemic cytokine
    responses during experimental human
    influenza A virus infection. J Clin Invest
    1998; 101:643–9.
    15. Skoner DP. Gentile DA, Patel A, Doyle WJ.
    Evidence for cytokine mediation of disease expression
    in adults experimentally infected with
    influenza A virus. J Infect Dis 1999; 180:10–4.
    16. Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden
    FG. Symptom pathogenesis during acute
    influenza: interleukin-6 and other cytokine responses.
    J Med Virol 2001; 64:262–8.
    17. Seo SH, Webby R, Webster RG. No apoptotic
    deaths and different levels of inductions of
    inflammatory cytokines in alveolar macrophages
    infected with influenza viruses. Virology
    2004; 329:270–9.
    18. Peiris JSM, Yu WC, Leung KH, et al. Re-emergence
    of fatal human influenza A subtype
    H5N1 disease. Lancet 2004; 363:617–9.
    19. Seo SH, Hoffmann E, Webster RG. Lethal
    H5N1 influenza viruses escape host anti-viral
    cytokine responses. Nat Med 2002; 8:950–4.
    20. Lipatov AS, Andreansky S, Webby RJ, et al.
    Pathogenesis of Hong Kong H5N1 influenza
    virus NS gene reassortants in mice: the role
    of cytokines and B- and T-cell responses. J
    Gen Virol 2005; 86:1121–30.
    21. Lee DCW, Cheung CY, Law AHY, Mok CKP,
    PeirisM, Lau ASY. p38 Mitogen-activatedprotein
    kinase–dependent hyperinduction of tumor
    necrosis factor alpha expression in response
    to avian influenza virus H5N1. J Virol
    2005; 79:10147–54.
    22. Kobasa D, Takada A, Shinya K, et al. Enhanced
    virulence of influenza A viruses with the
    haemagglutinin of the 1918 pandemic virus.
    Nature 2004; 431:703–7.
    23. Tumpey TM, Garcia-Sastre A, Taubenberger
    JK, et al. Pathogenicity of influenza viruses
    with genes from the 1918 pandemic virus:
    functional roles of alveolar macrophages and
    neutrophils in limiting virus replication and
    mortality in mice. J Virol 2005; 79:14933–44.
    24. Schonbeck U, Libby P. Inflammation, immunity,
    and HMG-CoA reductase inhibitors:
    statins as antiinflammatory agents? Circulation
    2004; 109:II18–26.
    25. Jain MK, Ridker PM. Anti-inflammatory effects
    of statins; clinical evidence and basic
    mechanisms. Nat Rev Drug Discov 2005; 4:
    26. Baigent C, Keech A, Kearney PM, et al. Efficacy
    and safety of cholesterol-lowering treatment:
    prospective meta-analysis of data from
    90,056 participants in 14 randomized trials of
    statins. Lancet 2005; 366:1267–78.
    27. Node K, Fujita M, Kitakaze M, Hori M, Liao
    JK. Short-term statin therapy improves cardiac
    function and symptoms in patients with
    idiopathic dilated cardiomyopathy. Circulation
    2003; 108:839–43.
    28. Wassmann S, Faul A, Hennen B, Scheller B,
    Bohm M, Nickering G. Rapid effect of 3-
    hydroxy-3-methylglutaryl coenzyme A reductase
    inhibition on coronary endothelial function.
    Circ Res 2003; 93:e98–103.
    29. Fang CH, Li JJ, Hui RT. Statins, like aspirin,
    should be given as early as possible in patients
    with acute coronary syndrome. Med Hypotheses
    2005; 64:192–6.
    30. Fonarow GC, Wright RS, Spencer FA, et al.
    Effect of statin use within the first 24 hours
    of admission for acute myocardial infarction
    on early morbidity and mortality. Am J Cardiol
    2005; 96:611–6.
    31. Harris MC, D’Angio CT, Gallagher PR, et al.
    Cytokine elaboration in critically ill infants
    with bacterial sepsis, necrotizing enterocolitis,
    or sepsis syndrome: correlation with clinical
    parameters of inflammation and mortality. J
    Pediatr 2005; 147:462–8.
    32. Kumar A, Kumar A, Michael P, et al. Human
    serum from patients with septic shock activates
    transcription factor STAT1, IRF1 and NF-kB
    and induces apoptosis in human cardiac myocytes.
    J Biol Chem 2005; 280:42619–26.
    33. MerxMW, Liehn EA, Janssens U, et al. HMGCoA
    reductase inhibitor simvastatin profoundly
    improves survival in a murine model
    of sepsis. Circulation 2004; 109:2560–5.
    34. MerxMW, Liehn EA, Graf J, et al. Statin treatment
    after onset of sepsis in a murine model
    improves survival. Circulation 2005; 112:
    35. Liappis AP, Kan VL, Rochester CG, Simon GL.
    The effect of statins on mortality in patients
    with bacteremia. Clin Infect Dis 2001; 33:
    36. Almog Y, Shefer A, Novack V, et al. Prior statin
    therapy is associated with a decreased rate of
    severe sepsis. Circulation 2004; 110:880–5.
    37. Kruger P, Fitzsimmons K, Cook D, Jones M,
    Nimmo G. Statin therapy is associated with
    fewer deaths in patients with bacteremia. Intensive
    Care Med 2006; 32:75–9.
    38. Hackam DG, Mamdani M, Li P, Redelmeier
    DA. Statins and sepsis in patients with cardiovascular
    disease: a population-basedcohort
    analysis. Lancet 2006; 367:413–8.
    39. Thomsen RW, Hundborg HH, Johnsen SP, et
    al. Statin use and mortality within 180 days
    after bacteremia: a population-based cohort
    study. Crit Care Med 2006; 34:1080–6.
    40. Mortensen EM, Restrepo MI, Anzueto A,
    Pugh J. The effect of prior statin use on 30-
    day mortality for patients hospitalized with
    community-acquired pneumonia. Respir Res
    2005; 6:82.
    41. Warnholtz A, Genth-Zotz S, Munzel T. Should
    treatment of sepsis include statins? Circulation
    2005; 111:1735–7.
    42. Buras JA, Holzmann B, Sitkovsky M. Animal
    models of sepsis: setting the stage. Nat Rev
    Drug Discov 2005; 854–65.
    Statins and Pandemic Influenza • CID 2006:43 (15 July) • 000
    43. Riedemann NC, Guo RF, Ward PA. Novel
    strategies for the treatment of sepsis. Nat Med
    2003; 9:517–24.
    44. Brunn GJ, Platt JL. The etiology of sepsis:
    turned inside out. Trends Mol Med 2006; 12:
    45. Goodman RB, Pugin J, Lee JS, Matthay MA.
    Cytokine-mediated inflammation in acute
    lung injury. Cytokine Growth Factor Rev 2003;
    46. Puneet P, Moochhala S, BhaXtia M. Chemokines
    in acute respiratory distress syndrome.
    Am J Physiol Lung Cell Mol Physiol
    2005; 288:L3–15.
    47. Rojas M,Woods CR, Mora AL, Xu J, Brigham
    KL. Endotoxin-induced lung injury in mice:
    structural, functional and biochemical responses.
    Am J Physiol Lung Cell Mol Physiol
    2005; 288:L333–41.
    48. Parsons PE, Matthay MA, Ware LB, Eisner
    MD, National Heart, Lung, Blood Institute
    Acute Respiratory Distress Syndrome Clinical
    Trial Network. Elevated plasma levels of soluble
    TNF receptors are associated with morbidity
    and mortality in patients with acute
    lung injury. AmJ Physiol Lung Cell Mol Physiol
    2005; 288:L426–31.
    49. Gon Y, Wood MR, Kiosses WB, et al. S1P3
    receptor–induced reorganization of epithelial
    tight junctions compromises lung barrier integrity
    and is potentiated by TNF. Proc Natl
    Acad Sci USA 2005; 102:9270–5.
    50. Jacobson JR, Dudek SM, Birukov KG, et al.
    Cytoskeletal activation and altered gene expression
    in endothelial barrier regulation by
    simvastatin. Am J Respir Cell Mol Biol
    2004; 30:662–70.
    51. Jacobson JR, Barnard JW, Grigoryev DN, Ma
    SF, Tuder RM, Garcia JG. Simvastatin attenuates
    vascular leak and inflammation in murine
    inflammatory lung injury. Am J Physiol
    Lung Cell Mol Physiol 2005; 288:L1026–32.
    52. Pirat A, Zeyneloglu P, Aldemir D, et al. Pretreatment
    with simvastatin reduces lung injury
    related to intestinal ischemia-reperfusion in
    rats. Anesth Analg 2006; 102:225–32.
    53. Yende S, Tuomanen EI, Wunderink R, et al.
    Preinfection systemic inflammatory markers
    and risk of hospitalization due to pneumonia.
    Am J Respir Crit Care Med 2005; 172:1440–6.
    54. de Lange DW, Bonten MJ. Can we predict
    septic shock in patients with hospital-acquired
    pneumonia? Crit Care 2005; 9:640–1.
    55. Fedson DS. Clinical and experimental studies
    of the molecular pathophysiology of influenza.
    In: Knobler SL, Mack A, Mahmoud A, Lemon
    SM, eds. The threat of pandemic influenza:
    are we ready? Washington DC: The National
    Academies Press, 2005:194–6.
    56. Fessler MB, Young SK, Jeyaseelan S, et al. A
    role for hydroxy-methylglutaryl coenzyme A
    reductase in pulmonary inflammation and
    host defense. Am J Respir Crit Care Med
    2005; 171:606–15.
    57. Vecchione C, Brandes RP. Withdrawal of 3-
    hydroxy-3-methylglutaryl coenzyme A reductase
    inhibitors elicits oxidative stress and induces
    endothelial dysfunction in mice. Circ
    Res 2002; 91:173–9.
    58. Gertz K, Laufs U, Lindauer U, et al. Withdrawal
    of statin treatment abrogates stroke
    protection in mice. Stroke 2003; 34:551–7.
    59. Enserink M. Infectious disease. Old drugs losing
    effectiveness against flu; could statins fill
    the gap? Science 2005; 309:1946–7.
    60. Ottolini MG, Blanco JC, Eichelberger MC, et
    al. The cotton rat provides a useful smallanimal
    model for the study of influenza virus
    pathogenesis. J Gen Virol 2005; 86:2823–30.
    61. Maines TR, Lu XH, Erb SM, et al. Avian influenza
    (H5N1) viruses isolated from humans
    in Asia in 2004 exhibit increased virulence in
    mammals. J Virol 2005; 79:11788–800.
    62. Tumpey TM, Basler CF, Aguilar PV, et al. Characterization
    of the reconstructed 1918 Spanish
    influenza pandemic virus. Science 2005; 310:
    63. Kash JC, Basler CF, Garcia-Sastre A, et al.
    Global host immune response: pathogenesis
    and transcriptional profiling of type A influenza
    viruses expressing the hemagglutinin and
    neuraminidase genes from the 1918 pandemic
    virus. J Virol 2004; 78:9499–511.
    64. Baskin CR, Garcia-Sastre A, Tumpey TM, et
    al. Integration of clinical data, pathology, and
    cDNA microarrays in influenza virus–infected
    pigtailed macques (Macaca nemestrina). J Virol
    2004; 78:10420–32.
    65. Peltola VT, Murti KG, McCullers JG. Influenza
    virus neuraminidase contributes to secondary
    bacterial pneumonia. J Infect Dis 2005;
    66. Rajendran L, Simons K. Lipid rafts and
    membrane dynamics. J Cell Sci 2005; 118:
    67. Sun X, Whittaker GR. Role for influenza virus
    envelope cholesterol in virus entry and infection.
    J Virol 2003; 77:12543–51.
    68. Nayak DP, Hui EK, Barman S, Assembly and
    budding of influenza virus. Virus Res 2004;
    69. Leser GP, Lamb RA. Influenza virus assembly
    and budding in raft-derived microdomains: a
    quantitative analysis of the surface distribution
    of HA, NA and M2 proteins. Virology 2005;
    70. Kawai T, Akira S. Innate immune recognition
    of viral infection. Nat Immunol 2006; 7:131–7.
    71. Nimmerjahn F, Dudziak D, Dirmeier U, et al.
    Active NF-kB signalling is a prerequisite for
    influenza virus infection. J Gen Virol 2004;
    72. Ludwig S, Pleschka S, Planz O, Wolff T. Ringing
    the alarm bells: signalling and apoptosis
    in influenza virus infected cells. CellMicrobiol
    2006; 8:375–86.
    73. LotzeMT, Tracey KJ. High-mobility groupbox
    1 protein (HMGB1): nuclear weapon in the
    immune arsenal. Nat Rev Immunol 2005; 5:
    74. Jiang JD, Liang J, Fan J, et al. Regulation of
    lung injury and repair by Toll-like receptors
    and hyaluronan. Nat Med 2005; 11:1173–9.
    75. Parikh SM, Mammoto T, Schultz A, et al. Excess
    circulating angiopoeitin-2 may contribute
    to pulmonary vascular leak in sepsis in humans.
    PLoS Med 2006; 3:e46.
    76. Mortensen EM, Restrepo MI, Anzueto A,
    Pugh JA. The impact of prior outpatient ACE
    inhibitor use on 30-day mortality for patients
    hospitalized with community-acquired pneumonia.
    BMC Pulm Med 2005; 5:12.
    77. Nickenig G. Should angiotension II receptor
    blockers and statins be combined? Circulation
    2004; 110:1013–20.
    78. Sonder SU, Mikkelsen M, Rieneck K, Hedegaard
    CJ, Bendtzen K. Effects of spironolactone
    on human blood mononuclear cells: mineralocortocoid
    receptor independent effects
    on gene expression and late apoptosis induction.
    Br J Pharmacol 2006; 148:46–53.
    79. Coimbra R, Melbostad H, LoomisW, et al. LPSinduced
    acute lung injury is attenuated by phosphodiesterase
    inhibition: effects on proinflammatory
    mediators, metalloproteinases, NF-kB
    and ICAM-1 expression. J Trauma 2006; 60:
    80. Cheung CY, Poon LL, Ng IH, et al. Cytokine
    responses in severe acute respiratory syndrome
    coronavirus–infected macrophages in
    vitro: possible relevance to pathogenesis. J Virol
    2005; 79:7819–26.
    81. Tseng CT, Perrone LA, Zhu H, Makino S, Peters
    CJ. Severe acute respiratory syndromeand
    the innate immune response: modulation of
    effector cell function without productive infection.
    J Immunol 2005; 174:7977–85.
    82. Kuba K, Imai Y Rao S, et al. A crucial role of
    angiotensin converting enzyme 2 (ACE2) in
    SARS coronavirus–induced lung injury. Nat
    Med 2005; 11:875–9.
    83. del Real G, Jimenez-Baranda S, Mira E, et al.
    Statins inhibit HIV-1 infection by down-regulating
    Rho activity. J Exp Med 2004; 200:
    84. Berenson A. Lipitor or generic? Billion-dollar
    battle looms. New York Times, 15 October

  • #2
    Re: Pandemic Influenza: A Potential Role for Statins (full article)

    That first sentence sure got my attention.....
    The next influenza pandemic may be imminent....
    "The next major advancement in the health of American people will be determined by what the individual is willing to do for himself"-- John Knowles, Former President of the Rockefeller Foundation


    • #3
      Re: Pandemic Influenza: A Potential Role for Statins (full article)

      Originally posted by AlaskaDenise
      That first sentence sure got my attention.....

      LOL! Dr. Fedson doesn't mince words.


      • #4
        Re: Pandemic Influenza: A Potential Role for Statins (full article)

        Thank you Brian for working so dilligently with Dr. Fedson these last months. Dr. Fedson (Dfed) has been a member here since 7/5/06 and I hope that your phone bill will be more reasonable!

        What a wonderful resource for the entire internet!


        • #5
          Re: Pandemic Influenza: A Potential Role for Statins (full article)

          Other statin information on FluTrackers - again - Thank you to members Dr. Brian Kopp, Dr. David Fedson, and Mingus.

          H5N1 Solutions Poll

          Influenza ("Bird Flu"), inflammation and anti-inflammatory/analgesic drugs.

          WHO's "POLYPILL": template for a Third World H5N1 approach?

          Dr. David Fedson is an internationally recognized expert on influenza vaccination and treatment....

          Cholesterol Drugs May Help Fight Influenza Pandemic (Update2)


          • #6
            Re: Pandemic Influenza: A Potential Role for Statins (full article)

            Originally posted by Florida1
            Other statin information on FluTrackers - again - Thank you to members Dr. Brian Kopp, Dr. David Fedson, and Mingus.

            H5N1 Solutions Poll

            Influenza ("Bird Flu"), inflammation and anti-inflammatory/analgesic drugs.

            WHO's "POLYPILL": template for a Third World H5N1 approach?

            Dr. David Fedson is an internationally recognized expert on influenza vaccination and treatment....

            Cholesterol Drugs May Help Fight Influenza Pandemic (Update2)
            Bumping this up for new forum members.


            • #7
              Re: Pandemic Influenza: A Potential Role for Statins (full article)

              Since the research about the cytokine storm likely being most responsible for the worst symptoms and potentially death in acute pandemic influenza, I have often wondered about the possibility of using a short course of prednisone to damp down the immune response. This would also be a cheap and readily available solution in addition to statins. Any thoughts?


              • #8
                Re: Pandemic Influenza: A Potential Role for Statins (full article)

                Originally posted by curious
                Since the research about the cytokine storm likely being most responsible for the worst symptoms and potentially death in acute pandemic influenza, I have often wondered about the possibility of using a short course of prednisone to damp down the immune response. This would also be a cheap and readily available solution in addition to statins. Any thoughts?
                Here's an excerpt which indicates that prednisone might not be very helpful in ARDS:

                Successful treatment of adult respiratory distress syndrome by histamine and prostaglandin blockade in a porcine Pseudomonas model.

                Sielaff TD, Sugerman HJ, Tatum JL, Blocher CR.

                Porcine Pseudomonas adult respiratory distress syndrome (ARDS) has been shown to respond to combination therapy of 150 mg of cimetidine, 12.5 mg/kg of ibuprofen, 10 mg/kg of diphenhydramine, 0.2 mg/kg of ketanserin, and 30 mg/kg of methylprednisolone (CIDKM or Poly-5) given at 20 and 120 minutes after the onset of a continuous infusion of liver Pseudomonas aeruginosa, 5 X 10(8) colony-forming units (CFU) ml at 0.3 ml/20 kg/min. The present study was designed to determine the minimal, effective therapy by selective deletion of individual agents from CIDKM. ...

                Pseudomonas alone produced severe ARDS with significant (p less than .05) decreases in PAO2 cardiac index, and systemic arterial pressure and significant increases in pulmonary artery pressure, extravascular lung water (EVLW) and scintigraphically determined pulmonary albumin flux measured as slope index (SI). Full therapy, CIDKM or Poly-5, showed significant improvement in all parameters. Deletion of methylprednisolone did not significantly effect any parameter measured. The deletion of ketanserin, leaving CID, did not alter treatment efficacy, except for a significant decline in cardiac index at 3 hours. Deletion of ibuprofen from CID resulted in a failure to reverse pulmonary arterial hypertension, hypoxemia, elevated EVLW, and increased SI. Removal of either cimetidine or diphenhydramine from CID resulted in significant increases in EVLW compared with control levels and SI compared with both control levels and CID. These results indicate that a combination of both histamine H1 and H2 receptor blockers and the cyclooxygenase inhibitor, ibuprofen, is effective and essential in the treatment of hypoxemia, early pulmonary hypertension, and pulmonary microvascular injury in this fulminant model of porcine Pseudomonas ARDS.


                • #9
                  Re: Pandemic Influenza: A Potential Role for Statins (full article)

                  I never thought I would have anything to offer in this thread, given the caliber of medical professionals responsible for this fabulous work. But, re: the prednisone question. Doctors working in 1997 in Hong Kong tried that approach for the first victims of H5N1 and found it exacerbated the response. This was published in "Hong Kong Journal of Medicine" in June of 2005. Let me see if I can find the article.

                  Hong Kong Med J 2005;11:189-99
                  Department of Microbiology, University of
                  Hong Kong, Queen Mary Hospital,
                  Pokfulam Road, Hong Kong
                  KY Yuen, FRCP, FRCPath
                  SSY Wong, MRCPath, DTM&H


                  Scroll down to page 8 and read 'Clinical Management".
                  Please do not ask me for medical advice, I am not a medical doctor.

                  Avatar is a painting by Alan Pollack, titled, "Plague". I'm sure it was an accident that the plague girl happened to look almost like my twin.
                  Thank you,
                  Shannon Bennett


                  • #10
                    Re: Pandemic Influenza: A Potential Role for Statins (full article)

                    Nice article Shannon. Good find. I wonder how many US centers if any, have an IRB approved protocol in place for statins or other therapies in H5N1. JT
                    Thought has a dual purpose in ethics: to affirm life, and to lead from ethical impulses to a rational course of action - Teaching Reverence for Life -Albert Schweitzer. JT


                    • #11
                      Re: Pandemic Influenza: A Potential Role for Statins (full article)

                      Thank you Shannon,

                      I have not done a MedLine search on the treatment of cytokine storm in association with pandemic influenza, but this is a valuable reference on the types of treatment that should be applied. Based on thisstudy, instead of prednisone, perhaps people should be adding Ibuprofen, Zantac and Benadryl to their over the counter armamentarium for the bird flu. Of course, one cannot discount the need for proper hydration and replacement of electrolytes lost after dehydration. Bird Flu could cause dehydration through high fever and diarrhea. Would powdered gatorade be useful in this regard to replace lost electrolytes?



                      • #12
                        Re: Pandemic Influenza: A Potential Role for Statins (full article)

                        Originally posted by curious
                        Based on thisstudy, instead of prednisone, perhaps people should be adding Ibuprofen, Zantac and Benadryl to their over the counter armamentarium for the bird flu.
                        Discussed here:

                        H5N1 Rx: ACE2 blocker + Tagamet + Advil + Benadryl (?)


                        • #13
                          Re: Pandemic Influenza: A Potential Role for Statins (full article)


                          I didn't mean to re-invent the wheel or step on any toes here. Has a consensus ever been arrived at for the use of these over the counter remedies should a bird flu pandemic arrive? I agree, the majority of the population (here in the US and third world) will not have access to anti-virals or a flu vaccine in a timely or cost-effective manner and it seems that if not contraindicated for other pre-existing conditions or interact with other necessary prescriptions that wouldn't it be a good idea to have some of these relatively cheap over the counter drugs on hand? Of course, anyone using these agents would have to be knowlegeable of their own medical conditions and any specific contraindications, but under the circumstances, wouldn't anything readily available such as these OTC medications potentially lessen the severity of the flu and save lives? I know the articles specifically referenced Ibuprofen (Advil or Motrin)cimetidine (Tagamet) and diphenhydramine (Benadryl). Wouldn't other H2 antagonists such as Zantac or Pepsid also be of help?

                          Meanwhile, I think I'll add these to my own pandemic preps (just in case).

                          Forever, Curious


                          • #14
                            Re: Pandemic Influenza: A Potential Role for Statins (full article)

                            Originally posted by curious

                            I didn't mean to re-invent the wheel or step on any toes here.
                            No, not at all! I'm sorry if I gave you that impression.

                            Has a consensus ever been arrived at for the use of these over the counter remedies should a bird flu pandemic arrive?
                            Unfortunately, no. I'm just a Podiatrist (foot surgeon) and other than this thread, I'm not aware this has been discussed anywhere else by competent clinicians, let alone tried.

                            I agree, the majority of the population (here in the US and third world) will not have access to anti-virals or a flu vaccine in a timely or cost-effective manner and it seems that if not contraindicated for other pre-existing conditions or interact with other necessary prescriptions that wouldn't it be a good idea to have some of these relatively cheap over the counter drugs on hand? Of course, anyone using these agents would have to be knowlegeable of their own medical conditions and any specific contraindications, but under the circumstances, wouldn't anything readily available such as these OTC medications potentially lessen the severity of the flu and save lives? I know the articles specifically referenced Ibuprofen (Advil or Motrin)cimetidine (Tagamet) and diphenhydramine (Benadryl). Wouldn't other H2 antagonists such as Zantac or Pepsid also be of help?
                            Honestly, we were hoping to get some clinicians to weigh in on this, one way or the other. So far, no luck.


                            • #15
                              Re: Pandemic Influenza: A Potential Role for Statins (full article)

                              I printed the article out and sent it to our pharmacy manager today. I wonder if it will get any response?
                              Upon this gifted age, in its dark hour,
                              Rains from the sky a meteoric shower
                              Of facts....They lie unquestioned, uncombined.
                              Wisdom enough to leech us of our ill
                              Is daily spun, but there exists no loom
                              To weave it into fabric..
                              Edna St. Vincent Millay "Huntsman, What Quarry"
                              All my posts to this forum are for fair use and educational purposes only.